AdvisorNet Financial Inc Raises Holdings in Becton, Dickinson and Company (NYSE:BDX)

AdvisorNet Financial Inc lifted its holdings in shares of Becton, Dickinson and Company (NYSE:BDXGet Rating) by 27.7% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 461 shares of the medical instruments supplier’s stock after purchasing an additional 100 shares during the period. AdvisorNet Financial Inc’s holdings in Becton, Dickinson and were worth $114,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of BDX. Norges Bank purchased a new position in shares of Becton, Dickinson and during the 4th quarter worth approximately $663,055,000. Mackenzie Financial Corp grew its stake in Becton, Dickinson and by 79.4% in the 1st quarter. Mackenzie Financial Corp now owns 2,365,111 shares of the medical instruments supplier’s stock worth $613,354,000 after acquiring an additional 1,046,400 shares during the period. BlackRock Inc. grew its stake in Becton, Dickinson and by 4.2% in the 4th quarter. BlackRock Inc. now owns 20,694,679 shares of the medical instruments supplier’s stock worth $5,204,300,000 after acquiring an additional 828,789 shares during the period. State Street Corp grew its stake in Becton, Dickinson and by 3.9% in the 4th quarter. State Street Corp now owns 12,705,205 shares of the medical instruments supplier’s stock worth $3,195,105,000 after acquiring an additional 480,684 shares during the period. Finally, Invesco Ltd. grew its stake in Becton, Dickinson and by 15.3% in the 1st quarter. Invesco Ltd. now owns 3,547,059 shares of the medical instruments supplier’s stock worth $943,516,000 after acquiring an additional 471,726 shares during the period. 86.74% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

BDX has been the subject of several recent analyst reports. Citigroup cut shares of Becton, Dickinson and from a “neutral” rating to a “sell” rating and lowered their target price for the stock from $265.00 to $235.00 in a research note on Monday, July 11th. The Goldman Sachs Group lifted their target price on shares of Becton, Dickinson and from $278.00 to $319.00 and gave the stock a “buy” rating in a research note on Tuesday, August 16th. Wells Fargo & Company upgraded shares of Becton, Dickinson and from an “equal weight” rating to an “overweight” rating and set a $275.00 price target on the stock in a report on Friday, June 24th. Morgan Stanley decreased their price target on shares of Becton, Dickinson and from $282.00 to $272.00 and set an “overweight” rating on the stock in a report on Friday, July 15th. Finally, Stifel Nicolaus decreased their price target on shares of Becton, Dickinson and from $290.00 to $280.00 in a report on Monday, July 18th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $277.63.

Insider Activity at Becton, Dickinson and

In other Becton, Dickinson and news, CEO Thomas E. Polen, Jr. sold 9,500 shares of the business’s stock in a transaction on Monday, August 15th. The shares were sold at an average price of $265.13, for a total value of $2,518,735.00. Following the transaction, the chief executive officer now owns 28,878 shares in the company, valued at approximately $7,656,424.14. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Becton, Dickinson and news, EVP David Hickey sold 475 shares of the business’s stock in a transaction on Monday, August 15th. The shares were sold at an average price of $265.00, for a total value of $125,875.00. Following the transaction, the executive vice president now owns 3,331 shares in the company, valued at approximately $882,715. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Thomas E. Polen, Jr. sold 9,500 shares of the business’s stock in a transaction on Monday, August 15th. The stock was sold at an average price of $265.13, for a total transaction of $2,518,735.00. Following the completion of the transaction, the chief executive officer now owns 28,878 shares in the company, valued at approximately $7,656,424.14. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 19,160 shares of company stock worth $5,036,751. 0.50% of the stock is currently owned by corporate insiders.

Becton, Dickinson and Stock Performance

NYSE:BDX opened at $238.01 on Thursday. The company has a current ratio of 1.35, a quick ratio of 0.90 and a debt-to-equity ratio of 0.58. The firm has a market capitalization of $67.88 billion, a price-to-earnings ratio of 41.04, a PEG ratio of 3.29 and a beta of 0.57. The firm’s fifty day simple moving average is $252.31 and its 200 day simple moving average is $254.20. Becton, Dickinson and Company has a twelve month low of $231.46 and a twelve month high of $280.62.

Becton, Dickinson and (NYSE:BDXGet Rating) last posted its earnings results on Thursday, August 4th. The medical instruments supplier reported $2.66 earnings per share for the quarter, beating the consensus estimate of $2.50 by $0.16. The business had revenue of $4.64 billion for the quarter, compared to analyst estimates of $4.47 billion. Becton, Dickinson and had a net margin of 8.88% and a return on equity of 14.55%. The business’s quarterly revenue was down 5.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.74 EPS. As a group, equities research analysts expect that Becton, Dickinson and Company will post 11.31 earnings per share for the current fiscal year.

Becton, Dickinson and Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 30th. Investors of record on Friday, September 9th will be issued a dividend of $0.87 per share. The ex-dividend date of this dividend is Thursday, September 8th. This represents a $3.48 annualized dividend and a dividend yield of 1.46%. Becton, Dickinson and’s payout ratio is 60.00%.

About Becton, Dickinson and

(Get Rating)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.

Further Reading

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDXGet Rating).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.